Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years
In Long-Term Exploratory Analysis, TAK-003 Prevented 84% of Hospitalizations and 61% of Symptomatic Dengue Illness Overall
13-Jun-2022 -
Takeda announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years ...
dengue fever
vaccine candidates